



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/898,750

07/03/2001

James G. Wetmur

Enz-49(P2) (C)

7451

28171 7590 11/25/2008
ENZO BIOCHEM, INC.
527 MADISON AVENUE (9TH FLOOR)
NEW YORK, NY 10022

EXAMINER

LU, FRANK WEI MIN

ART UNIT

PAPER NUMBER

1634

MAIL DATE

DELIVERY MODE

11/25/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 09/898,750	Applicant(s) WETMUR ET AL.	
	Examiner FRANK W. LU	Art Unit 1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 August 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 117-180 is/are pending in the application.
- 4a) Of the above claim(s) 126,133,138,142,143 and 149-178 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 117-125, 127-132, 134-137, 140, 141,144-148, 179, and 180 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 03 July 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1634

DETAILED ACTION

Response to Amendment

1. Applicant's response to the office action filed on August 6, 2008 has been entered. The claims pending in this application are claims 117-180 wherein claims 126, 133, 138, 142, 143, and 149-178 have been withdrawn due to restriction and species election requirements mailed on August 17, 2005. Rejection and/or objection not reiterated from the previous office action are hereby withdrawn in view of the response filed on August 6, 2008. Claims 117-125, 127-132, 134-137, 140, 141, 144-148, 179, and 180 will be examined.

Election/Restrictions

2. This application contains claims 149-178 drawn to an invention nonelected with traverse in the reply filed on August 6, 2008. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claim Objections

3. Claim 148 is objected to because of the following informality: "118-125; 127-132; 134-137; 140, 141, and 144-147" should be "118-125, 127-132, 134-137, 140, 141, and 144-147".

Appropriate correction is required.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1634

5. New Matter

Claims 117-125, 127-132, 134-137, 140, 141, 144-148, 179, and 180 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.

The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The limitation “wherein said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex” are added to the newly amended independent claim 117. Since the limitation “wherein said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex” can be read as that said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex of a triplex displacer-recipient complex formed by said displacer and said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex, and page 16, line 30, page 19, lines 17-24 of specification suggested by applicant does not describe such claim recitation, there is a new matter in claim 117.

MPEP 2163.06 notes “IF NEW MATTER IS ADDED TO THE CLAIMS, THE EXAMINER SHOULD REJECT THE CLAIMS UNDER 35 U.S.C. 112, FIRST PARAGRAPH - WRITTEN DESCRIPTION REQUIREMENT. *IN RE RASMUSSEN*, 650 F.2D 1212, 211 USPQ 323 (CCPA 1981).” MPEP 2163.02 teaches that “Whenever the issue arises, the fundamental factual inquiry is whether a claim defines an invention that is clearly conveyed to those skilled in the art at the time the application was filed...If a claim is amended to include subject matter, limitations, or terminology not present in the application as filed, involving a departure from, addition to, or deletion from the disclosure of the application as filed, the examiner should conclude that the claimed subject matter is not described in that application.” MPEP 2163.06 further notes “WHEN AN AMENDMENT IS FILED IN REPLY TO AN OBJECTION OR REJECTION BASED ON 35 U.S.C. 112, FIRST

Art Unit: 1634

PARAGRAPH, A STUDY OF THE ENTIRE APPLICATION IS OFTEN NECESSARY TO DETERMINE WHETHER OR NOT “NEW MATTER” IS INVOLVED. *APPLICANT SHOULD THEREFORE SPECIFICALLY POINT OUT THE SUPPORT FOR ANY AMENDMENTS MADE TO THE DISCLOSURE*” (emphasis added).

Response to Arguments

In page 11, third paragraph bridging to page 12, second paragraph of applicant's remarks, applicant argues that “[T]he specification contains a detailed discussion of single stranded displacers which are not hybridized to a linker strand and that are capable of initiating triplex formation. (See Specification at page 16, line 30). The single-stranded displacer strand contains at least one modified nucleotide. (See Specification page 17, line 27 to page 18, line 16). As with the recipient polynucleotide duplex, the change to the nucleotide in the polynucleotide duplex of a triplex displacer-recipient complex will occur when the new strand is introduced. In addition, Applicants respectfully submit that the labeling of the displacer-recipient complex is irrelevant to the subject matter of claim 117. The displacer recipient complex of the present invention comprises several sections, each with a varying number of nucleic acid strands. The central portion of the complex comprises the initial portion of the overhang of the displacer strand which is complementary to and binds to the double-stranded recipient molecule. This results in a triple-stranded central portion. The downstream portion of the displacer recipient comprises the displacer-linker duplex which is double stranded. The upstream portion of the displacer recipient molecule comprises the displaced nucleic acid which is single stranded. Thus, the phrase ‘displacer recipient complex’ can not be defined in terms of a duplex or triplex. Rather, it is a descriptive term encompassing the molecule that exists after hybridization of the displacer linker composition to the recipient duplex. A person of skill in the art would have the ability to

Art Unit: 1634

visualize the resulting molecule in the absence of any label. Thus, claim 17 satisfies the written description requirement”.

These arguments have been fully considered but they are not persuasive toward the withdrawal of the rejection. First, since the limitation “wherein said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex” can be read as that said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex of a triplex displacer-recipient complex formed by said displacer and said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex, and page 16, line 30, page 19, lines 17-24 of specification suggested by applicant does not describe such claim recitation, there is a new matter in claim 117. Second, claim 117 does not require that the downstream portion of the displacer recipient comprises the displacer-linker duplex which is double stranded and the upstream portion of the displacer recipient molecule comprises the displaced nucleic acid which is single stranded as argued by applicant.

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Art Unit: 1634

7. Claims 117-119, 121, 125, 134-136, 144, 145, 179, and 180 are rejected under 35 U.S.C. 102(e) as being anticipated by Lin *et al.*, (US Patent No. 5,214,136, filed on February 20, 1990).

Regarding claim 117, Lin *et al.*, teach a nucleic acid displacer composition comprising an isolated oligo-or polynucleotide displacer (ie., 5'-P-CCC-TCT-TTT-TTT-CCP in Table 4), said oligo- or polynucleotide displacer comprising two or more sequences: a) at least one first sequence (ie., CCC-TCT in 5'-P-CCC-TCT-TTT-TTT-CCP in Table 4) which complexes with said recipient polynucleotide duplex; b) at least one second sequence (ie., TT-TTT in 5'-P-CCC-TCT-TTT-TTT-CCP in Table 4), said second sequence being complementary to at least a portion of one strand of said recipient polynucleotide duplex and being base-paired with said portion, comprising one or more modified nucleotides (ie., CP in 3' of 5'-P-CCC-TCT-TTT-TTT-CCP) that increase stability; and comprising one or more nucleotides that form a mismatch (ie., T in 6 position in 5'-P-CCC-TCT-TTT-TTT-CCP in Table 4) with said strand of the recipient polynucleotide duplex as recited in the claim (see columns 8-10 and Table 4). Since the nucleic acid displacer taught by Lin *et al.*, has an ability to change at least one nucleotide or a nucleotide sequence in a recipient polynucleotide duplex which is available in nature when the displacer is introduced to the recipient polynucleotide duplex, the recipient polynucleotide duplex and the displacer-recipient complex recited in the claim are not parts of a nucleic acid displacer composition, and the phrase "wherein said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide" is not a structural limitation of the claim but is a functional limitation of the claim, Lin *et al.*, teach that said displacer changes at least one nucleotide or a

Art Unit: 1634

nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex as recited in the claim.

Regarding claims 118, 119, and 121, Lin *et al.*, teach that said second sequence is adjacent to said first sequence as recited in claim 118 wherein said second sequence is separated from said first sequence by from 1 to 5 intervening moieties (ie., T in 6 position in 5'-P-CCC-TCT-TTT-TTT-CCP in Table 4) as recited in claim 119 and said intervening moieties are nucleotides as recited in claim 121 (see columns 8-10 and Table 4).

Regarding claim 125, Lin *et al.*, teach that least one of said nucleotides complementary to said strand of the recipient polynucleotide duplex is modified to increase the stability of the displacer-recipient complex, wherein the modification is in the second sequence (ie., CP in 3' of 5'-P-CCC-TCT-TTT-TTT-CCP) (see columns 8-10 and Table 4).

Regarding claims 134-136, since Lin *et al.*, teach that 5'-P-CCC-TCT-TTT-TTT-CCP is resistant to snake venom phosphodiesterase digestion, it is known that snake venom phosphodiesterase is an exonuclease (see page 1 of attachment for snake venom phosphodiesterase), and claim 134 does not require that at least one moiety attached to a terminus of the oligo or polynucleotide is different from the one modified nucleotide recited in claim 117, Lin *et al.*, disclose at least one moiety attached to a terminus of the oligo or polynucleotide, said moiety conferring exonuclease resistance to the terminus to which it is attached as recited in claim 134 wherein said moiety is attached to a terminal nucleotide (ie., anthraquinone of P in 3' of 5'-P-CCC-TCT-TTT-TTT-CCP) as recited in claim 135 and said moiety is indirectly attached to a terminal nucleotide as recited in claim 136 (ie., by P in 3' of 5'-P-CCC-TCT-TTT-TTT-CCP) (see columns 8-10 and Table 4).

Art Unit: 1634

Regarding claims 144 and 145, Lin *et al.*, teach further comprising a modification (ie., a fluorescent label) which permits detection of the displacer-recipient complex as recited in claim 144 wherein said modification comprises a member selected from the group consisting of non-radioactive labels, radioactive labels, fluorescent labels, chemiluminescent labels, enzymes and targets for detection as recited in claim 145 (see column 5, lines 51-64).

Regarding claim 179, since the recipient polynucleotide duplex recited in the claim is not a part of a nucleic acid displacer composition and the nucleic acid displacer taught by Lin *et al.*, has an ability to changes at least one nucleotide or a nucleotide sequence in a recipient polynucleotide duplex which is available in nature, claim 179 is anticipated by Lin *et al.*.

Regarding claim 180, since the claim does not require that the oligo-or polynucleotide displacer is a duplex, Lin *et al.*, teach that the ligo-or polynucleotide displacer comprises a displacer strand (ie., CCC-TCT in 5'-P-CCC-TCT-TTT-TTT-CCP in Table 4) and a linker strand (ie., TTT-TTT-CCP in 5'-P-CCC-TCT-TTT-TTT-CCP in Table 4) as recited in claim 180.

Therefore, Lin *et al.*, teach all limitations recited in claims 117-119, 121, 125, 134-136, 144, 145, 179, and 180.

Response to Arguments

In page 12, last paragraph bridging to page 13, last paragraph of applicant's remarks, applicant argues that "[L]in teaches oligonucleotides derivatized to at least one anthraquinone at a position other than the 5' terminus. These compounds enhance hybridization to target DNA or RNA without the loss of specificity while providing enhanced stability to nucleases. The Examiner points to Table 4 in his analysis of the Lin patent. A close reading of the portion of Example 5--'Specificity of Hybridization' (data summarized in Table 4) describes conventional

Art Unit: 1634

hybridization of the modified oligomers to RNA. Thus, the modified oligomers were hybridized to *single-stranded* RNA complexes. (See Col. 9, lines 9-12). A duplex is formed only after binding of the modified oligomers. In contrast, the present invention requires binding of the displacer composition to a recipient polynucleotide *duplex*. The displacer complex is complementary to and base pairs with one strand of the recipient polynucleotide duplex. Claim 117 clearly recites the structural limitation of a recipient polynucleotide duplex. Lin, therefore, does not recite each and every limitation of claim 117 and is therefore does not anticipate the currently claimed invention”.

These arguments have been fully considered but they are not persuasive toward the withdrawal of the rejection. First, although Lin *et al.*, do not directly teach changes at least one nucleotide or a nucleotide sequence in the recipient polynucleotide duplex, since the nucleic acid displacer taught by Lin *et al.*, has an ability to change at least one nucleotide or a nucleotide sequence in the recipient polynucleotide duplex which is available in nature when the displacer is introduced to the recipient polynucleotide duplex, the recipient polynucleotide duplex and the displacer-recipient complex recited in claim 117 are not parts of a nucleic acid displacer composition, and the phrase “wherein said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex” recited in claim 117 is not a structural limitation of the claim but is a functional limitation of the claim, Lin *et al.*, do teach that said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex as recited in the claim and a recipient polynucleotide duplex is a structural limitation as argued by applicant is incorrect.

Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 146 and 147 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lin *et al.*, as applied to claims 117-119, 121, 125, 134-136, 144, 145, 179, and 180 above, and further in view of Dattagupta *et al.*, (US Patent No. 4,737,454, published on April 12, 1988).

The teachings of Lin *et al.*, have been summarized previously, *supra*.

Lin *et al.*, do not disclose that said modification in claim 144 is selected from the group consisting of biotin moieties, phosphorothioate linkages and antigens as recited in claim 146 and a modification which allows capture of the displacer-recipient complex by affinity chromatography as recited in claim 147.

Art Unit: 1634

Regarding claims 146 and 147, Since Dattagupta *et al.*, teach that a nucleic acid probe can be labeled with hapten or biotin, an enzyme such as a β -galactosidase or horse radish peroxidase, a fluorescent radical, a phycobiliprotein, a luminescent radical, or a radioisotope (see abstract) and it is known that biotin binds to avidin, Dattagupta *et al.*, disclose that said modification (ie., biotin) in claim 144 is selected from the group consisting of biotin moieties, phosphorothioate linkages and antigens as recited in claim 146 and a modification which allows capture of the displacer-recipient complex by affinity chromatography (ie., the affinity chromatography comprising avidin) as recited in claim 147.

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to have made the displacer recited in claims 146 and 147 wherein said modification is biotin moieties and the modification (ie., biotin) which allows capture of the displacer-recipient complex by affinity chromatography (ie., the affinity chromatography comprising avidin) in view of the prior art of Lin *et al.*, and Dattagupta *et al.*. One having ordinary skill in the art would have been motivated to do so because the simple replacement of one kind of label (ie., the fluorescent label taught by Lin *et al.*, see column 5, lines 51-64) from another kind of label (ie., the biotin label taught by Dattagupta *et al.*,) during the process of labeling the displacer recited in claims 146 and 147, in the absence of convincing evidence to the contrary, would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made since the label taught by Lin *et al.*, and the label taught by Dattagupta *et al.*, are used for the same purpose (ie., labeling a nucleic acid probe).

Furthermore, the motivation to make the substitution cited above arises from the expectation that the prior art elements will perform their expected functions to achieve their

Art Unit: 1634

expected results when combined for their common known purpose. Support for making the obviousness rejection comes from the M.P.E.P. at 2144.07 and 2144.09.

Also note that there is no invention involved in combining old elements in such a manner that these elements perform in combination the same function as set forth in the prior art without giving unobvious or unexpected results. *In re Rose* 220 F.2d. 459, 105 USPQ 237 (CCPA 1955).

Response to Arguments

In page 14, first paragraph bridging to page 16, first paragraph of applicant's remarks, applicant argues that "[A]s explained above, Lin does not teach a nucleic acid displacer composition which binds or complexes with a recipient polynucleotide duplex, as required by claim 117. Dattagupta does not cure the deficiencies of Lin. Like Lin, Dattagupta teaches only single stranded recipient molecules. Example 7, 'Assay for the Label after DNA-DNA Hybridization' describes treating nucleic acids to form single-stranded products before contacting with the labeled probe. (See col 12, lines 9-16). The references do not render the claims obvious because a person of ordinary skill in the art would have no motivation to combine the references, regardless of the type of label incorporated into the molecule. A person of skill in the art would have no reasonable expectation of success when combining the references because neither Lin nor Dattagupta teach a nucleic acid displacer composition which binds to or complexes with a recipient polynucleotide duplex. Claims 146 and 147 are not obvious over the combination of Lin and Dattagupta".

These arguments have been fully considered but they are not persuasive toward the withdrawal of the rejection. First, although Lin *et al.*, do not directly teach changes at least one nucleotide or a nucleotide sequence in the recipient polynucleotide duplex, since the nucleic acid

Art Unit: 1634

displacer taught by Lin *et al.*, has an ability to change at least one nucleotide or a nucleotide sequence in the recipient polynucleotide duplex which is available in nature when the displacer is introduced to the recipient polynucleotide duplex, the recipient polynucleotide duplex and the displacer-recipient complex recited in claim 117 are not parts of a nucleic acid displacer composition, and the phrase “wherein said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex” recited in claim 117 is not a structural limitation of the claim but is a functional limitation of the claim, Lin *et al.*, do teach that said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced into the recipient polynucleotide duplex as recited in claim 117 and a recipient polynucleotide duplex is a structural limitation as argued by applicant is incorrect. Second, applicant has no evidence to show that the nucleic acid displacer taught by Lin *et al.*, is not able to form a complex with a polynucleotide duplex in nature. Third, there is a motivation for combining Lin *et al.*, and Dattagupta *et al.*, together (see above office action).

10. Claim 148 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lin *et al.*, as applied to claims 117-119, 121, 125, and 134-136 above.

The teachings of Lin *et al.*, have been summarized previously, *supra*.

Lin *et al.*, do not disclose an artificially constructed polynucleotide hybrid comprising a naturally occurring recipient polynucleotide duplex hybridized to the nucleic acid displacer composition of claim 118 as recited in claim 148.

However, it would have been *prima facie* obvious to one having ordinary skill in the art

Art Unit: 1634

at the time the invention was made to have made an artificially constructed polynucleotide hybrid comprising a naturally occurring recipient polynucleotide duplex hybridized to the nucleic acid displacer composition of claim 118 as recited in claim 148 by hybridizing the nucleic acid displacer composition of claim 118 to a naturally occurring double stranded DNA. One having ordinary skill in the art would have been motivated to do so because Lin *et al.*, have tested the stabilities of the oligonucleotides coupled to anthraquinone *in vitro* and *in vivo* (see column 7, lines 49-51) and oligonucleotide sequences modified by conjugation to at least one unsubstituted or substituted anthraquinone at other than the 5' terminus have favorable properties in enhancing hybridization to target DNA or RNA without loss of specificity and show enhanced stability to nucleases (see abstract) and one having ordinary skill in the art would select a naturally occurring recipient polynucleotide duplex such as a naturally occurring double stranded DNA for making the artificially constructed polynucleotide hybrid recited in claim 148 based on his or her experimental requirements. One having ordinary skill in the art at the time the invention was made would have a reasonable expectation of success to make an artificially constructed polynucleotide hybrid comprising a naturally occurring recipient polynucleotide duplex hybridized to the nucleic acid displacer composition of claim 118 as recited in claim 148 by hybridizing the nucleic acid displacer composition of claim 118 to a naturally occurring double stranded DNA.

Response to Arguments

In page 15, second and third paragraphs of applicant's remarks, applicant argues that "[A]s explained above, neither Lin nor Dattagupta teach a double stranded recipient polynucleotide duplex, a structural component required by claim 117 (from which claim 148

Art Unit: 1634

ultimately depends). A person of ordinary skill in the art would have no motivation to combine the references, regardless of whether the polynucleotide is naturally occurring or artificially constructed. Thus, there would be no reasonable expectation of success when combining the references because neither Lin nor Dattagupta teach a nucleic acid displacer composition which binds to or complexes with a recipient polynucleotide duplex. Claim 148 is not obvious over the combination of Lin and Dattagupta”.

These arguments have been fully considered but they are not persuasive toward the withdrawal of the rejection. First, although Lin *et al.*, do not directly teach changes at least one nucleotide or a nucleotide sequence in the recipient polynucleotide duplex, since the nucleic acid displacer taught by Lin *et al.*, has an ability to change at least one nucleotide or a nucleotide sequence in the recipient polynucleotide duplex which is available in nature when the displacer is introduced to the recipient polynucleotide duplex, the recipient polynucleotide duplex and the displacer-recipient complex recited in claim 117 are not parts of a nucleic acid displacer composition, and the phrase “wherein said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex” recited in claim 117 is not a structural limitation of the claim but is a functional limitation of the claim, Lin *et al.*, do teach that said displacer changes at least one nucleotide or a nucleotide sequence in said recipient polynucleotide duplex when the displacer is introduced to the recipient polynucleotide duplex as recited in claim 117 and a recipient polynucleotide duplex is a structural limitation as argued by applicant is incorrect. Second, applicant has no evidence to show that the nucleic acid displacer taught by Lin *et al.*, is

Art Unit: 1634

not able to form a complex with a polynucleotide duplex in nature. Third, there is a motivation for rejecting claim 148 (see above office action).

Conclusion

11. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

12. No claim is allowed.

13. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is (571)273-8300.

Art Unit: 1634

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746.

The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571)272-0735.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

/Frank W Lu /
Primary Examiner, Art Unit 1634
November 10, 2008